• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一项关于机器学习在成人 Ph 阳性急性淋巴细胞白血病异基因干细胞移植后复发预测中应用的初步研究。

A pilot study of implication of machine learning for relapse prediction after allogeneic stem cell transplantation in adults with Ph-positive acute lymphoblastic leukemia.

机构信息

Department of Bone Marrow Transplantation of Adults, RM Gorbacheva Research Institute, Pavlov University, Lev Tolstoy Str., 6/8, Saint-Petersburg, Russia, 197022.

出版信息

Sci Rep. 2023 Oct 5;13(1):16790. doi: 10.1038/s41598-023-43950-w.

DOI:10.1038/s41598-023-43950-w
PMID:37798335
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10556079/
Abstract

The posttransplant relapse in Ph-positive ALL increases the risk of death. There is an unmet need for instruments to predict the risk of relapse and plan prophylaxis. In this study, we analyzed posttransplant data by machine learning algorithms. Seventy-four Ph-positive ALL patients with a median age of 30 (range 18-55) years who previously underwent allo-HSCT, were retrospectively enrolled. Ninety-three percent of patients received prophylactic/preemptive TKIs after allo-HSCT. The values of the BCR::ABL1 level at serial assessments and over variables were collected in specified intervals after allo-HSCT. They were used to model relapse risk with several machine-learning approaches. GBM proved superior to the other algorithms and provided a maximal AUC score of 0.91. BCR::ABL1 level before and after allo-HSCT, prediction moment, and chronic GvHD had the highest value in the model. It was shown that after Day + 100, both error rates do not exceed 22%, while before D + 100, the model fails to make accurate predictions. As a result, we determined BCR::ABL1 levels at which the relapse risk remains low. Thus, the current BCR::ABL1 level less than 0.06% in patients with chronic GvHD predicts low risk of relapse. At the same time, patients without chronic GVHD after allo-HSCT should be classified as high risk with any level of BCR::ABL1. GBM model with posttransplant laboratory values of BCR::ABL1 provides a high prediction of relapse after allo-HSCT in the era of TKIs prophylaxis. Validation of this approach is warranted.

摘要

Ph 阳性 ALL 移植后复发会增加死亡风险。因此,需要有工具来预测复发风险并制定预防措施。本研究采用机器学习算法分析移植后数据。回顾性纳入 74 例中位年龄为 30 岁(18-55 岁)的 Ph 阳性 ALL 患者,这些患者此前接受过allo-HSCT,93%的患者在 allo-HSCT 后接受预防性/抢先 TKI。在 allo-HSCT 后指定时间间隔内收集了连续评估和变量值的 BCR::ABL1 水平值,并用几种机器学习方法对复发风险进行建模。GBM 优于其他算法,提供了 0.91 的最大 AUC 评分。BCR::ABL1 水平、allo-HSCT 前后、预测时刻和慢性 GvHD 在模型中具有最高价值。结果表明,在第 +100 天之后,错误率均不超过 22%,而在第 +100 天之前,模型无法做出准确预测。因此,我们确定了复发风险保持较低水平的 BCR::ABL1 水平。因此,慢性 GvHD 患者当前的 BCR::ABL1 水平<0.06%预测复发风险低。同时,allo-HSCT 后无慢性 GVHD 的患者无论 BCR::ABL1 水平如何,均应归类为高风险。在 TKI 预防时代,基于移植后 BCR::ABL1 实验室值的 GBM 模型可对 allo-HSCT 后复发进行高度预测。需要对此方法进行验证。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3bde/10556079/5645951069e3/41598_2023_43950_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3bde/10556079/5645951069e3/41598_2023_43950_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3bde/10556079/5645951069e3/41598_2023_43950_Fig1_HTML.jpg

相似文献

1
A pilot study of implication of machine learning for relapse prediction after allogeneic stem cell transplantation in adults with Ph-positive acute lymphoblastic leukemia.一项关于机器学习在成人 Ph 阳性急性淋巴细胞白血病异基因干细胞移植后复发预测中应用的初步研究。
Sci Rep. 2023 Oct 5;13(1):16790. doi: 10.1038/s41598-023-43950-w.
2
Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.异基因造血干细胞移植后巨细胞病毒再激活与移植后存活至第100天的急性髓系白血病患者复发风险降低相关:日本造血细胞移植学会移植相关并发症工作组
Biol Blood Marrow Transplant. 2015 Nov;21(11):2008-16. doi: 10.1016/j.bbmt.2015.07.019. Epub 2015 Jul 26.
3
Patients with Philadelphia-positive leukemia with BCR-ABL kinase mutations before allogeneic transplantation predominantly relapse with the same mutation.在异基因移植前患有费城染色体阳性白血病且存在BCR-ABL激酶突变的患者,主要会以相同的突变形式复发。
Biol Blood Marrow Transplant. 2015 Jan;21(1):184-9. doi: 10.1016/j.bbmt.2014.09.012. Epub 2014 Oct 6.
4
[Risk Factors of Leukemia-free Survival in Ph ALL Patients with Allogeneic Hematopoietic Stem Cell Transplantation].[异基因造血干细胞移植的Ph+急性淋巴细胞白血病患者无白血病生存的危险因素]
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2017 Dec;25(6):1787-1792. doi: 10.7534/j.issn.1009-2137.2017.06.038.
5
Allogeneic Hematopoietic Stem Cell Transplantation for Adult Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia in Second Complete Remission.异基因造血干细胞移植治疗费城染色体阴性成人急性 B 淋巴细胞白血病第二次完全缓解。
Transplant Cell Ther. 2022 Jun;28(6):326.e1-326.e10. doi: 10.1016/j.jtct.2022.03.017. Epub 2022 Mar 17.
6
Relapse Prevention with Tyrosine Kinase Inhibitors after Allogeneic Transplantation for Philadelphia Chromosome-Positive Acute Lymphoblast Leukemia: A Systematic Review.酪氨酸激酶抑制剂在费城染色体阳性急性淋巴细胞白血病异基因移植后的复发预防中的应用:系统评价。
Biol Blood Marrow Transplant. 2020 Mar;26(3):e55-e64. doi: 10.1016/j.bbmt.2019.09.022. Epub 2019 Sep 23.
7
Prognostic significance of a normal karyotype in adult patients with BCR-ABL1-positive acute lymphoblastic leukemia in the tyrosine kinase inhibitor era.酪氨酸激酶抑制剂时代 BCR-ABL1 阳性成人急性淋巴细胞白血病中正常核型的预后意义。
Clinics (Sao Paulo). 2020 Nov 11;75:e2011. doi: 10.6061/clinics/2020/e2011. eCollection 2020.
8
In-vivo T-cell depleted reduced-intensity conditioned allogeneic haematopoietic stem-cell transplantation for patients with acute lymphoblastic leukaemia in first remission: results from the prospective, single-arm evaluation of the UKALL14 trial.体内T细胞去除的低强度预处理异基因造血干细胞移植用于首次缓解期急性淋巴细胞白血病患者:UKALL14试验前瞻性单臂评估结果
Lancet Haematol. 2022 Apr;9(4):e276-e288. doi: 10.1016/S2352-3026(22)00036-9.
9
Mutations in epigenetic regulators are involved in acute lymphoblastic leukemia relapse following allogeneic hematopoietic stem cell transplantation.表观遗传调控因子的突变与异基因造血干细胞移植后急性淋巴细胞白血病复发有关。
Oncotarget. 2016 Jan 19;7(3):2696-708. doi: 10.18632/oncotarget.6259.
10
The impact of tyrosine kinase inhibitors on allogeneic hematopoietic stem cell transplantation for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.酪氨酸激酶抑制剂对费城染色体阳性成人急性淋巴细胞白血病患者异基因造血干细胞移植的影响
Leuk Res. 2021 Oct;109:106647. doi: 10.1016/j.leukres.2021.106647. Epub 2021 Jun 18.

引用本文的文献

1
Machine-Learning Predictive Tool for the Individualized Prediction of Outcomes of Hematopoietic Cell Transplantation for Sickle Cell Disease: Registry-Based Study.镰状细胞病造血细胞移植结局个体化预测的机器学习预测工具:基于登记处的研究
JMIR AI. 2025 Sep 15;4:e64519. doi: 10.2196/64519.
2
Survival Prediction in Allogeneic Haematopoietic Stem Cell Transplant Recipients Using Pre- and Post-Transplant Factors and Computational Intelligence.利用移植前后因素和计算智能预测异基因造血干细胞移植受者的生存情况
J Cell Mol Med. 2025 Aug;29(16):e70672. doi: 10.1111/jcmm.70672.

本文引用的文献

1
An mHealth-Based Health Management Information System Among Health Workers in Volta and Eastern Regions of Ghana: Pre-Post Comparison Analysis.加纳沃尔特和东部地区卫生工作者中基于移动健康的健康管理信息系统:前后对比分析
JMIR Med Inform. 2022 Aug 31;10(8):e29431. doi: 10.2196/29431.
2
20-Year Steady Increase in Survival of Adult Patients with Relapsed Philadelphia-Positive Acute Lymphoblastic Leukemia Post Allogeneic Hematopoietic Cell Transplantation.异基因造血细胞移植后费城染色体阳性急性淋巴细胞白血病复发的成年患者 20 年生存率持续增高。
Clin Cancer Res. 2022 Mar 1;28(5):1004-1012. doi: 10.1158/1078-0432.CCR-21-2675.
3
Natural and Synthetic Estrogens in Chronic Inflammation and Breast Cancer.
慢性炎症与乳腺癌中的天然和合成雌激素
Cancers (Basel). 2021 Dec 31;14(1):206. doi: 10.3390/cancers14010206.
4
Blinatumomab maintenance after allogeneic hematopoietic cell transplantation for B-lineage acute lymphoblastic leukemia.异基因造血细胞移植后用于 B 系急性淋巴细胞白血病的blinatumomab 维持治疗。
Blood. 2022 Mar 24;139(12):1908-1919. doi: 10.1182/blood.2021013290.
5
Asciminib and ponatinib combination in Philadelphia chromosome-positive acute lymphoblastic leukemia.阿西替尼与波纳替尼联合用于费城染色体阳性急性淋巴细胞白血病的治疗
Leuk Lymphoma. 2021 Dec;62(14):3558-3560. doi: 10.1080/10428194.2021.1966787. Epub 2021 Aug 18.
6
Long-term follow-up of blinatumomab in patients with relapsed/refractory Philadelphia chromosome-positive B-cell precursor acute lymphoblastic leukaemia: Final analysis of ALCANTARA study.费城染色体阳性 B 细胞前体急性淋巴细胞白血病患者接受blinatumomab 治疗的长期随访:ALCANTARA 研究的最终分析。
Eur J Cancer. 2021 Mar;146:107-114. doi: 10.1016/j.ejca.2020.12.022. Epub 2021 Feb 13.
7
Application of Sparse Representation to Bartlett Spectra for Improved Direction of Arrival Estimation.将稀疏表示应用于巴特利特谱以改进到达方向估计
Sensors (Basel). 2020 Dec 25;21(1):77. doi: 10.3390/s21010077.
8
Application of machine learning in the management of acute myeloid leukemia: current practice and future prospects.机器学习在急性髓系白血病管理中的应用:现状与展望。
Blood Adv. 2020 Dec 8;4(23):6077-6085. doi: 10.1182/bloodadvances.2020002997.
9
Blinatumomab + ponatinib for relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia in adults.博纳吐单抗联合波纳替尼治疗成人复发/难治性费城染色体阳性急性淋巴细胞白血病
Leuk Lymphoma. 2021 Mar;62(3):620-629. doi: 10.1080/10428194.2020.1844198. Epub 2020 Nov 6.
10
Is 0.6% Reasonable as the Minimum Requirement of the Graft-to-recipient Weight Ratio Regardless of Lobe Selection in Adult Living-donor Liver Transplantation?成人活体肝移植中,无论选择哪个肝叶,0.6%是否可以作为移植物与受者体重比的最低要求?
Transplantation. 2021 Sep 1;105(9):2007-2017. doi: 10.1097/TP.0000000000003472.